Nicole C A J van de Kar Selected Research

eculizumab

3/2022	Proposal for individualized dosing of eculizumab in atypical hemolytic uremic syndrome: patient friendly and cost-effective.
1/2022	Eculizumab impairs killing of Neisseria meningitidis serogroup B in atypical hemolytic uremic syndrome patients vaccinated with MenB-4C.
1/2021	Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome.
1/2020	Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?
1/2020	Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient.
11/2019	Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
4/2019	Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
1/2019	Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire.
1/2019	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.
12/2017	Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicole C A J van de Kar Research Topics

Disease

17	Atypical Hemolytic Uremic Syndrome 03/2022 - 07/2012
9	Infections 12/2021 - 09/2014
7	Hemolytic-Uremic Syndrome 01/2022 - 01/2017
7	Thrombotic Microangiopathies 11/2019 - 08/2013
5	Proteinuria 01/2020 - 12/2014
4	Inflammation (Inflammations) 01/2022 - 03/2005
4	Hemolysis 11/2021 - 07/2012
4	Meningococcal Infections 01/2019 - 04/2014
3	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2022 - 01/2020
3	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 01/2022 - 01/2020
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 03/2005
2	Glomerulonephritis 01/2022 - 01/2020
2	Acute Kidney Injury (Acute Renal Failure) 12/2021 - 01/2020
2	Hematuria 01/2020 - 12/2014
2	Idiopathic Pulmonary Fibrosis 01/2019 - 10/2017
1	Escherichia coli Infections 01/2022
1	Chronic Renal Insufficiency 01/2020
1	Myasthenia Gravis 01/2019
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2019
1	Hypertension (High Blood Pressure) 12/2017
1	Pneumonia (Pneumonitis) 12/2014
1	Whooping Cough (Pertussis) 12/2014
1	Thrombotic Thrombocytopenic Purpura 01/2014
1	Thrombocytopenia (Thrombopenia) 01/2014
1	Pulmonary Hypertension 08/2013
1	Peritonitis 03/2013
1	Inborn Genetic Diseases (Disease, Hereditary) 02/2013
1	Hemophilia A (Haemophilia) 02/2013
1	Rare Diseases (Rare Disease) 07/2012
1	Dyslipidemias (Dyslipidemia) 03/2005
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2005

Drug/Important Bio-Agent (IBA)

15	eculizumab FDA Link 03/2022 - 07/2012
12	Complement System Proteins (Complement)IBA 01/2021 - 08/2012
8	Shiga Toxin (Shigella Toxin)IBA 01/2022 - 07/2017
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2012
2	Dichlorodiphenyldichloroethane (DDD)IBA 01/2022 - 01/2020
2	Heme (Haem)IBA 01/2022 - 01/2020
2	ProperdinIBA 11/2021 - 01/2019
2	pirfenidoneIBA 01/2019 - 10/2017
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2019 - 12/2017
2	Complement Factor H (Factor H)IBA 08/2012 - 07/2012
1	Pharmaceutical PreparationsIBA 03/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Puromycin AminonucleosideIBA 01/2022
1	Protamines (Protamine Sulfate)FDA Link 01/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2020
1	GlucocorticoidsIBA 01/2020
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2020
1	nintedanibIBA 01/2019
1	CreatinineIBA 12/2017
1	Complement Inactivating AgentsIBA 12/2017
1	Complement C5 (Complement 5)IBA 10/2015
1	AnaphylatoxinsIBA 08/2015
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 08/2015
1	Complement C3 (C3 Complement)IBA 12/2014
1	thiamine triphosphorate (TTP)IBA 01/2014
1	Prednisone (Sone)FDA LinkGeneric 01/2014
1	Bortezomib (Velcade)FDA Link 01/2014
1	Rituximab (Mabthera)FDA Link 01/2014
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 08/2013
1	Factor VIII (Coagulation Factor VIII)IBA 02/2013
1	chemotactic factor inactivatorIBA 08/2012
1	Fibrinogen (Factor I)FDA Link 08/2012
1	AutoantibodiesIBA 08/2012
1	Membrane Cofactor ProteinIBA 08/2012
1	ThrombomodulinIBA 08/2012
1	Complement Factor B (Factor B)IBA 08/2012
1	calcium phosphateIBA 03/2005

Therapy/Procedure

6	Therapeutics 01/2020 - 07/2012
4	Kidney Transplantation 01/2020 - 07/2012
2	Plasma Exchange 01/2014 - 07/2012
1	Nephrectomy 01/2020
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Extracorporeal Membrane Oxygenation 12/2014
1	Peritoneal Dialysis 03/2013